Heart-Lung drug gets Long-Term safety check in 800 patients

NCT ID NCT07436689

ENROLLING_BY_INVITATION Disease control Sponsor: Tenax Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 02, 2026 · Last updated May 17, 2026 · Updated 10 times

Summary

This study offers continued access to an oral medication called levosimendan for people with pulmonary hypertension linked to heart failure. About 800 participants who previously took the drug in an earlier study will be monitored for side effects over the long term. The goal is to understand how safe the drug is when used for an extended period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Tenax Investigational Site

Chicago, Illinois, 60611, United States
Tenax Investigational Site

Minneapolis, Minnesota, 55455, United States
Tenax Investigational Site

Rochester, Minnesota, 55905, United States
Tenax Investigational Site

St Louis, Missouri, 63136, United States
Tenax Investigational Site

Charleston, South Carolina, 29425, United States

Conditions

Explore the condition pages connected to this study.

PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF